- Biotechnology
- Friday, 05 Jun 2020
Healios Successfully Establishes Proprietary Universal Donor Cell Research Line
Healios plans to combine its UDC technology with its existing efforts in next-generation cancer-targeting immune cells, ophthalmology, organ buds and so on to create a line of regenerative medicine therapies with the highest possible safety and efficacy profile.
Typically, transplanted cells trigger an immune rejection response in patients whose HLA type does not match that of the cells. Therefore, doctors must administer an immunosuppressant drug during transplantation, which increases the burden on the patient's body. To avoid the administration of immunosuppressants, it is preferable to utilize autologous iPS cells produced by the patient's own cells, but the production process both takes a long time and is very expensive.
UDCs are iPS cells created using gene-editing technology that allows them to reduce the body's immune rejection response. The production of Healios' UDCs involves the removal of certain HLA genes that elicit a rejection response, the introduction of an immunosuppression gene to improve immune evasion, and the addition of a suicide gene serving as a safety mechanism, each in an allogeneic iPS cell. This next-generation technology platform allows for the creation of regenerative pharmaceutical products with enhanced safety and a lower risk of immune rejection, while preserving the inherent ability of iPS cells to replicate themselves continuously and their pluripotency in differentiating into various other kinds of cells.
Plans are underway at Healios to promote the internal development of regenerative pharmaceutical products that utilize UDCs and further reinforce the Company's pipeline. It is committed to working towards the early completion of a clinical-grade UDC line that meets global approvability standards.
Related Industry Updates
Bioprocess Technology Market is expected to reach US$ 77,090.05 million by 2028
Jun 08, 2023
MiRNA Kits Market 2020: Strategic Assessment, Latest Innovations, Drivers, Restraints, Challenges to 2027
Mar 23, 2021
SFA Therapeutics Announces FDA Approval To Begin IND Trial
Jun 29, 2020
Chemiluminescence Immunoassay (CLIA) Analyzers Market to Witness Promising Growth Opportunities by 2021-2027 | Global Share, Size, Manufacturer Data, Production, Future Plans, Strategies, Deployment Model etc.
Mar 19, 2021
Asia Pacific Prenatal & Newborn Genetic Testing Market Forecast up to 2027with Great CAGR value of 11.6%| Business Market Insights
Feb 17, 2021
South America Organic Fertilizers Market Revenue Status and Outlook 2019-2027 Detailed in New Research Report| AgroCare Canada, Biostar Renewables, Italpollina SpA, ScottsMiracle-Gro and Suståne Natural Fertilizer
Feb 11, 2021
Protein Crystallization and Crystallography Market Size will Escalate Rapidly in the Near Future 2020: Forecast 2027
Apr 01, 2021